IFF Invests $30 Million to Expand Regional Footprint in Singapore
IFF (NYSE: IFF) today announced the opening of its new Singapore Innovation Center, the first in its global network of research, creative and application centers to integrate the technologies, capabilities and expertise of all four business divisions: Nourish, Health & Biosciences, Scent and Pharma Solutions. At nearly 11,000 square meters, it is IFF’s largest in the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221012006035/en/
IFF Invests $30 Million to Expand Regional Footprint in Singapore (Photo: Business Wire)
Its launch—following IFF’s newly operational Singapore Flexiblend plant in Tuas—marks the latest in the company’s nearly US$30 million investment into Singapore. The two sites are part of a series of aggressive investments IFF is making to accelerate innovation, broaden its co-creation capabilities, drive speed to market and enhance accessibility to customers across Asia.
“By 2030, Asia is projected to account for 60 percent of global economic growth,” said Frank Clyburn, chief executive officer of IFF. “For IFF, Asia has demonstrated consistent growth, and we see tremendous opportunity in the future.”
“Just this year, we’ve opened innovation centers in the U.S., Latin America, Europe and now Singapore, demonstrating our commitment to advance scientific discovery globally. Together, these significant investments will fast forward innovation across our broad portfolio, supporting our customers in creating differentiated, new-to-world solutions that benefit people and planet.”
Situated in Singapore’s premier biomedical research hub, the ultra-modern center features more than ten creation, design and analytical laboratories, a collaboration studio, and culinary and demo kitchens, providing customers with full sensory capabilities to support each stage of the process from ideation through commercialization. It has one of the biggest dairy processing pilot plants in Southeast Asia, replicating large-scale industrial production processes. The center also houses IFF’s global innovation center for fabric care powders and personal wash, the largest scent evaluation facility worldwide, and is the first IFF location to support all scent product categories.
“In this integrated space, we will unlock cross-divisional synergies, fast-tracking innovation and accelerating new growth opportunities,” said Ramon Brentan, IFF Singapore Innovation Center site leader, and vice president, Greater Asia regional general manager, Scent, IFF. “We are very well positioned to offer a comprehensive portfolio for Asian consumers, offering end-to-end solutions that consumers love in food, beverage, health, biosciences and scent. This center is a true powerhouse of innovation and will further strengthen our position as a strategic co-creation partner to our customers in Asia.”
The state-of-the-art Singapore Flexiblend plant—which had its grand opening on Oct. 12—will increase supply robustness and provide customized biotechnology solutions catered to the grain processing and animal nutrition and health customers in the region.
“We are delighted that IFF chose Singapore to establish its largest innovation facility in Asia. Along with their new Flexiblend plant, these investments demonstrate how innovation and solution-driven companies can leverage Singapore’s talent, scientific capabilities, and access to regional markets to develop new, sustainable products for Asian consumers,” said Mr. Tan Kong Hwee, executive vice president, Singapore Economic Development Board (EDB).
“In Singapore’s push towards environmentally sustainable growth opportunities in food, wellbeing, home and consumer care, EDB will partner like-minded companies such as IFF for their growth plans and create interesting jobs for Singaporeans in these areas.”
IFF is present in 14 countries across Greater Asia and has operated in Singapore since 1969. The Singapore Innovation Center is part of IFF’s network of more than 50 research, creative and design centers, which help bring differentiated and integrated solutions to customers around the world.
Cautionary Statement under the Private Securities Litigation Reform Act of 1995
This press release contains “forward-looking statement” within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “will,” expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as the impact of the new center to our business. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet.Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
© 2022 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221012006035/en/
Contact information
Michael DeVeau
Chief Investor Relations & Communications Officer 212.708.7164
Media.request@iff.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
